Synthetische Cannabinoide: eine narrative Übersicht

Zusammenfassung

Die seit einigen Jahren verfügbaren synthetischen Cannabinoiden (SC) zählen zu den NPS (neue psychoaktive Substanzen). Bei SC handelt es sich um eine sehr heterogene Gruppe von Substanzen mit häufig stark agonistischer Wirkung auf Cannabisrezeptoren, die beim Konsum vielfältige, zum Teil gesundheitsgefährdende Wirkungen auslösen können. Die SC gelten als die am häufigsten konsumierten NPS. Ziel dieser narrativen Übersicht ist es, aktuelle Kenntnisse hinsichtlich Pharmakologie, Epidemiologie, Wirkungen, Diagnostik und Risiko von Konsumstörungen sowie Behandlungsansätzen darzustellen.

Abstract

Synthetic cannabinoids (SC), which have been available for several years, are classified as NPS (new psychoactive substances). SC represent a highly heterogeneous group of substances that, when consumed, elicit a variety of effects, some of which pose significant health risks. SC are considered the most frequently consumed NPS. The aim of this narrative review is to present current knowledge regarding the pharmacology, epidemiology, effects, diagnostics, and risks of substance use disorders, as well as treatment approaches.

Schlüsselwörter

Neue pychoaktive Substanzen - Synthetische Cannabinoide - Cannabisrezeptor Agonisten - Epidemiologie - Klinische Wirkungen

Keywords

new psychoaktive substances - synthetic cannabinoids - cannabis receptor agonists - epidemiology - clinical effects

Publication History

Article published online:
13 May 2025

• Literatur

• 1 Gomes de Matos E, Hannemann TV, Atzendorf J. et al. The consumption of new psychoactive substances and methamphetamine – analysis of data from 6 German federal states. Dtsch Arztebl Int 2018; 115: 49-55
• 2 Bonnet U, Mahler H. Synthetic cannabinoids: spread, addiction biology & current perspective of personal health hazard. Fortschr Neurol Psychiatr 2015; 83: 221-231
• 3 European Monitoring Centre for Drugs and Drug Addiction. European Drug Report. Trends and Developments. Luxembourg: Publications Office of the European Union; 2024 https://www.euda.europa.eu/publications/european-drug-report/2024/harm-reduction_en accessed 27.2.2025
• 4 Hohmann N, Mikus G, Czock D. Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals. Dtsch Arztebl Int 2014; 111: 139-147
• 5 Brown JD, Rivera Rivera KJ, Hernandez LYC. et al. Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions. J Clin Pharmacol 2021; 61: S37-S52
• 6 Alzu’bi A, Almahasneh F, Khasawneh R. et al. The synthetic cannabinoids menace: a review of health risks and toxicity. Eur J Med Res 2024; 29: 49
• 7 Bell C, Slim J, Flaten HK. et al. Synthetic cannabinoid use: an emerging health concern. Clin Pract Cases Emerg Med 2015; 1: 61-66
• 8 Pierre JM. Cannabis, synthetic cannabinoids, and psychosis risk: What the evidence says. Curr Addict Rep 2017; 4: 136-143
• 9 Auwärter V, Dresen S, Weinmann W. et al. ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs?. J Mass Spectrom 2009; 44: 832-837
• 10 Alves VL, Gonçalves JL, Aguiar J. et al. The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review. Crit Rev Toxicol 2020; 50: 359-382
• 11 Seitz NN, John L, Atzendorf J. et al. Kurzbericht Epidemiologischer Suchtsurvey 2015. Tabellenband: Konsum illegaler Drogen, multiple Drogenerfahrung und Hinweise auf Konsumabhängigkeit und -missbrauch nach Geschlecht und Alter im Jahr 2018. München: IFT Institut für Therapieforschung; 2019
• 12 Liechti M. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Med Wkly 2015; 145: w14043
• 13 Scherbaum N, Schifano F, Bonnet U. New psychoactive substances (NPS) – a challenge for the addiction treatment services. Pharmacopsychiatry 2017; 50: 116-122
• 14 Bundesministerium der Justiz (BMJ). Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe (NpSG). BGBl I 2016; S. 2615 [Internet]. Available from https://www.gesetze-im-internet.de/npsg/
• 15 Preuss UW, Schoett K. Cathinone und synthetische Cannabinoide. Suchttherapie 2022; 23: 94-106
• 16 Hancox JC, Copeland CS, Harmer SC. et al. New synthetic cannabinoids and the potential for cardiac arrhythmia risk. J Mol Cell Cardiol Plus 2023; 6: 100049
• 17 Davidson C, Opacka-Juffry J, Arevalo-Martin A. et al. Spicing Up Pharmacology: A Review of Synthetic Cannabinoids From Structure to Adverse Events. Adv Pharmacol 2017; 80: 139-170
• 18 El Helaly E, Edin H. Toxicity of Synthetic Cannabinoids: A Case Study. Am J Forensic Med Pathol 2022; 38: 123-130
• 19 Roque-Bravo R, Silva RS, Malheiro RF. et al. Synthetic Cannabinoids: A Pharmacological and Toxicological Overview. Annu Rev Pharmacol Toxicol 2023; 63: 187-209
• 20 Martinotti G, Santacroce R, Papanti D. et al. Synthetic cannabinoids: psychopharmacology, clinical aspects, psychotic onset. CNS Neurol Disord Drug Targets 2017; 16: 567-575
• 21 Zimmermann US, Winkelmann PR, Pilhatsch M. et al. Withdrawal phenomena and dependence syndrome after the consumption of ‘spice gold’. Dtsch Arztebl Int 2009; 106: 464-467
• 22 Bouter C, Ott FW, Günther D. et al. Chronic exposure to a synthetic cannabinoid alters cerebral brain metabolism and causes long-lasting behavioral deficits in adult mice. J Neural Transm 2023; 130: 1013-1027
• 23 Cohen K, Mama Y, Rosca P. et al. Chronic Use of Synthetic Cannabinoids Is Associated With Impairment in Working Memory and Mental Flexibility. Front Psychiatry 2020; 11: 602
• 24 Craft S, Ferris JA, Barratt MJ. et al. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis. Psychopharmacology 2022; 239: 1349-1357
• 25 Cohen K, Rosenzweig S, Rosca P. et al. Personality Traits and Psychotic Proneness Among Chronic Synthetic Cannabinoid Users. Front Psychiatry 2020; 11: 355
• 26 Hermanns-Clausen M, Kneisel S, Szabo B. et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013; 108: 534-544
• 27 on behalf of the NEPTUNE Expert Group. Abdulrahim D, Bowden-Jones O. Guidance on the Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances. London: Novel Psychoactive Treatment UK Network (NEPTUNE). 2015